Ropes & Gray represented Foghorn Therapeutics in its registered direct offering of 12,743,039 shares of common stock $5.51 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 7,220,794 shares of its common stock for total gross proceeds of approximately $110 million. The closing was announced in a May 22 press release.
Foghorn is a Cambridge, Mass., biopharmaceutical company developing a novel class of oncology medicines that target genetically-determined dependencies within the chromatin regulatory system.
The Ropes & Gray team included capital markets partner Rachel Phillips, life sciences partner Marc Rubenstein, tax partner Eric Behl-Remijan, and life sciences regulatory & compliance partner Kellie Combs.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
